Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2021.0305

Mini-Review

Discovery of novel drugs and biomarkers drive breakthrough matched combinatorial therapy.

William CS CHO, MD, PhD.

 

Abstract
Next Generation Sequencing (NGS) and CRISPR -Cas technologies are transforming biomedical research towards Precision Medicine [1-3]
Particularly in cancer, an explosion in genome and transcriptome analysis has not only created a revolutionary roadmap but also is initiating to guide Precision Oncology [4] .
The potential and challenges of whole genome and transcriptome analysis in time and space by developing and validating novel prediction biomarkers and novel targeted drugs[5, 6] are described. Moreover, combination drug therapy matched the individual patients set of actionable mutations [7] are discussed Optimal individualized meaningful treatment is also discussed in this review.

(Citation: Gastric & Breast Cancer 2021; 16(1): 46-55)

Back  

 

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 1 January 2021